Prevalence of human parvovirus B19 in Chinese plasma pools for manufacturing plasma derivatives.

ABSTRACT:

Background

Human parvovirus B19 (B19V) is a frequent contaminant of blood and plasma-derived medicinal products. To ensure the quality and safety of plasma-derived products, European regulations, Plasma Protein Therapeutics Association (PPTA) standard and FDA guidelines require testing of manufacturing plasma for parvovirus B19 DNA to limit the load of this virus. In China, however, there have been no related documentation and technical guiding principles for monitoring B19V, moreover, an adequate level of information on the prevalence of B19V in Chinese plasma donations is not available.

Findings

By using an in-house quantitative polymerase chain reaction (qPCR) assay adapted for all three genotypes of B19V, 235 source plasma pools from three regional different Chinese manu

SUBMITTER: Jia J 

PROVIDER: S-EPMC4596515 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature